
    
      The trial is a randomized, double blind, placebo controlled, parallel group trial in subjects
      diagnosed with fibromyalgia in accordance with the American College of Rheumatology. Total
      duration is up to twenty-two (22) weeks of trial participation. Subjects will undergo a
      screening and withdrawal/washout period lasting up to five (5) weeks combined followed by
      baseline period lasting one (1) week. Total treatment duration will be fourteen (14) weeks
      followed by a two week safety follow-up post treatment period. During the screening and
      withdrawal/washout period, no study medication will be given; however rescue medication up to
      4 grams per day of acetaminophen (paracetemol) will be allowed.
    
  